Ms. Samira Sakhia reports

NOTICE OF KNIGHT THERAPEUTICS' SECOND QUARTER 2025 RESULTS CONFERENCE CALL

Knight Therapeutics Inc. will release its second quarter 2025 financial results on Thursday, Aug. 7, 2025, prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date:   Thursday, Aug. 7, 2025

Time:  8:30 a.m. ET

Telephone numbers

Toll-free:  1-888-699-1199

International:  1-416-945-7677

Webcast:  on the Knight Therapeutics website

This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay:   An archived replay will be available for 30 days on the Knight Therapeutics website.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.